



MEDICAL TIPS

DIABIZ TABLET

Issue XI, No. 41, 2022

Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF

McDowell K *et.al. Eur J Heart Fail.* 2022; 24(6):1066-1076.

- Uric acid (UA) levels are frequently elevated in patients with heart failure and reduced ejection fraction (HFrEF).
- Reduction in UA is desirable in HFrEF and sodium–glucose cotransporter 2 inhibitors may have this effect; this was analyzed in the present study.
- Compared with placebo, Dapagliflozin reduced UA by 0.84 mg/dL ($p < 0.001$) over 12 months and improved outcomes.
- The finding that Dapagliflozin lowered UA in patients with HFrEF is important because hyperuricemia is common in this population

Dapagliflozin is associated with reduced UA and improved outcomes in patients with HFrEF

